

1 **Lower probability and shorter duration of infections after Covid-19 vaccine**  
2 **correlate with anti-SARS-CoV-2 circulating IgGs**

3

4 Chiara Ronchini<sup>a</sup>, Sara Gandini<sup>b</sup>, Sebastiano Pasqualato<sup>b</sup>, Luca Mazzarella<sup>b</sup>, Federica Facciotti<sup>b</sup>,  
5 Marina Mapelli<sup>b</sup>, IEO Covid Team<sup>b,c,\*</sup>, Gianmaria Frige<sup>a</sup>, Rita Passerini<sup>c</sup>, Luca Pase<sup>d</sup>, Silvio  
6 Capizzi<sup>e</sup>, Fabrizio Mastrilli<sup>e</sup>, Roberto Orecchia<sup>f</sup>, Giacchino Natoli<sup>b</sup>, Pier Giuseppe Pelicci<sup>b</sup>

7

8 <sup>a</sup>*Clinical Genomics, European Institute of Oncology IRCCS, Milan, Italy*

9 <sup>b</sup>*Department of Experimental Oncology, European Institute of Oncology IRCCS, Milano, Italy*

10 <sup>c</sup>*Division of Laboratory Medicine, European Institute of Oncology IRCCS, Milan, Italy*

11 <sup>d</sup>*Occupational Medicine, European Institute of Oncology IRCCS, Milan, Italy*

12 <sup>e</sup>*Medical Administration, CMO, IEO, European Institute of Oncology, IRCCS, Milan, Italy*

13 <sup>f</sup>*Scientific Directorate, European Institute of Oncology IRCCS, Milan, Italy*

14

15 **Correspondence to:**

16 Chiara Ronchini or Pier Giuseppe Pelicci

17 [chiara.ronchini@ieo.it](mailto:chiara.ronchini@ieo.it), [piergiuseppe.pelicci@ieo.it](mailto:piergiuseppe.pelicci@ieo.it)

18 Department of Experimental Oncology, European Institute of Oncology

19 Via Adamello 16, 20139 Milan, Italy

20

21 **\*IEO Covid Team** (members listed in alphabetical order):

22 Federica Bellerba, Chiara Bozzetti, Stefania Brandini, Thelma Capra, Valentina Cecatiello,

23 Giuseppe Ciossani, Errico D'Elia, Giuseppina De Feudis, Mirko Doni, Karin J. Ferrari, Laura

24 Ferrari, Laura Furia, Barbara A. Gallo, Donatella Genovese, Elvira Gerbino, Stefania Guerini,

25 Maria G. Jodice, Cinzia Massaro, Mariangela Massaro, Davide Merli, Claudia Miccolo, Erika

26 Mileti, Manuela Moia, Francesca Montani, Silvia Monzani, Andrea Moro, Lorena Moretti, Adeline  
27 Ngounou Ngassa, Daniela Osti, Isabella Pallavicini, Rossana Piccioni, Elena Prosperini, Sara  
28 Raimondi, Cristina Richichi, Mauro Romanenghi, Adriana Salvaggio, Costanza Savino, Cristina  
29 Simone, Cristina Spinelli, Massimo Stendardo, Erika Tenderini, Cecilia Toscani, Gianluca Tripodi,  
30 Alessandro Verrecchia, Clara Visintin, Marika Zanotti

31

## 32 **Abstract**

33 The correlation between immune responses and protection from SARS-CoV-2 infections and its  
34 duration remains unclear. We performed a sanitary surveillance at the European Institute of  
35 Oncology (IEO) in Milan over a 17 months period. Pre-vaccination, in 1,493 participants, we scored  
36 266 infections (17.8%) and 8 possible reinfections (3%). Post-vaccination, we identified 30  
37 infections in 2,029 vaccinated individuals (1.5%). We report that the probability of infection post-  
38 vaccination is i) significantly lower compared to natural infection, ii) associated with a significantly  
39 shorter median duration of infection than that of first infection and reinfection, iii) anticorrelated  
40 with circulating antibody levels.

41

## 42 **Introduction**

43 SARS-CoV-2 pandemic has resulted in more than 220 million infections and 4.5 million deaths  
44 worldwide (Worldometer COVID-19 coronavirus pandemic.  
45 <https://www.worldometers.info/coronavirus>). SARS-CoV-2 vaccination induces strong humoral [1,  
46 2] and cellular [3] immunity and its high effectiveness has been shown in different contexts and  
47 populations [4-9]. Knowing the duration and extent of the protection from SARS-CoV-2 infection  
48 in individuals who have recovered from COVID-19 or have received the SARS-CoV-2 vaccination  
49 is critical to determine the future dynamics of SARS-CoV-2 circulation and have direct impacts on  
50 non-pharmaceutical interventions, public health control measures and vaccination strategies. These  
51 pieces of information, however, are still an open issue.

52

## 53 **Study design**

54 We performed systematic sanitary surveillance of the personnel working at the European Institute  
55 of Oncology (IEO), a large comprehensive cancer center in Milan, Northern Italy. Starting from  
56 April 2020, all workers, including health-care, support staff, administrative and research personnel,  
57 were tested for SARS-CoV-2 infection by quantitative PCR (qPCR) detection of viral genes, using  
58 the Allplex SARS-CoV-2 Assay (Seegene) on nasopharyngeal or saliva samples. Humoral  
59 immunity was measured by testing levels of IgGs against the receptor binding domain (RBD) of the  
60 spike protein using an in-house ELISA assay [10]. Our assay showed high sensitivity (95.2 %) and  
61 specificity (97.6%), that allowed monitoring IgG levels over time in healthy people as well as in  
62 Covid-19 patients with accuracy and reproducibility (see Supplementary Materials and Methods for  
63 details and [10]). 1,493 participants were initially enrolled into the study starting from April 2020  
64 and monitored before the vaccination campaign, which started on January 7<sup>th</sup>, 2021. 2,029  
65 individuals, including the first cohort, were then vaccinated and monitored until June 2021  
66 (characteristics of our study cohorts are reported in Table S1; timing of tests is described in  
67 Supplementary materials – ‘Procedures’ section and Supplementary Figure 1).

## 68 **SARS-CoV-2 infections or re-infections prior to vaccination**

69 In the pre-vaccination phase of our screening, we detected 266 SARS-CoV-2 infections (17.8%,  
70 266/1,493). Multivariate logistic models were used to identify independent variables associated  
71 with infections during follow-up. While age, COVID-19-symptoms pre-study or a positive PCR-test  
72 at baseline did not show significant association, nurse/physician vs. other professionals (researchers,  
73 technicians, administratives) were highly correlated with increased probability of infection  
74 ( $P < 0.0001$ ). Notably, subjects that were IgG+ at the time of enrollment (T0; Supplementary Figure  
75 S2) had 66% significantly lower probability of having a positive swab (OR=0.34, 95%CI: 0.14-  
76 0.80,  $P = 0.014$ , Supplementary Table S4).

77 We also observed 8 putative re-infections (8/266; ~3%) (Supplementary Table S2). Re-infections  
78 were defined as two PCR-positive samples interspersed with >1 PCR-negative sample. 5  
79 individuals (all IgG+) had reinfection at >60 days. 7 of the 8 re-infected subjects were IgG+ at the  
80 time of enrollment (T0; Supplementary Figure S2). Frequency of re-infection with respect to the  
81 status of IgG at time of enrollment was ~9% (7/80) in the IgG+ and 25% (1/4) in the IgG- subjects  
82 (difference is not statistically significant, Fisher exact test  $P = 0.335$ ; Table 2). 6 (4/5 IgG+) showed  
83 qPCR-positivity to only 1 of the 3 viral-genes tested and with Ct cycles >30. When considering  
84 only individuals testing positive for more than one SARS-CoV-2 gene in the PCR assay,  
85 frequencies of re-infection decreased significantly (2/266, <1%; 3% vs 0% for IgG+ vs IgG-).

86

## 87 **SARS-CoV-2 infections in vaccinated subjects**

88 2,029 subjects were tested post-vaccination with the Pfizer BNT162b2 or Astra Zeneca (AZ)  
89 vaccines. 90% subjects completed the two doses of BNT162b2, and 181 received a single or double  
90 dose of AZ. We observed a high rate of vaccination effectiveness, as measured by circulating anti-  
91 SARS-CoV-2 RBD IgGs 1 week post-vaccination, with: i) high antibody levels in the entire  
92 population (median ~5 fold increased over the threshold; min=1 and max=12.5) and across each  
93 age-group (age range: 19-81y/o); and ii) only 1.9% (39/2,029) of non-responders (IgG levels <0.28)

94 (Figure 1). IgG levels inversely correlated with age, with the lowest levels (median of 7.9) in  
95 subjects >70 (median of 20.0 in the age group 19-29; Figure 1). Moreover, levels of IgG  
96 monotonically declined over time post-vaccination, though 95.3% (1303/1367) or 98.4%  
97 (1030/1047) of tested individuals showed IgG levels above the threshold at 3 or 4 months post-  
98 vaccination, respectively (median of 2.22 and 1.57, respectively; Figure 1).

99 In the 2,029 vaccinated subjects, we identified 30 cases (1.5%) of molecularly-detectable infections  
100 (Table 1B). 4 had received only one dose of the AZ vaccine, while all others had completed the two  
101 doses of the BNT162b2. Notably, the probability of infection after vaccination was significantly  
102 lower than in the non-vaccinated subjects (1.47% vs 9.52%;  $P<0.0001$ ; Table 2), confirming the  
103 effectiveness of vaccination [4-9]. Infections were detected in all age groups except for the oldest  
104 (median 47.4 years old; min 23 and max 62; Table 1B). Time of infection varied from few days  
105 post-vaccination to >4 months after completion of the vaccination protocol (min 5 days, max 139,  
106 median 55 days post-vaccination, Table 1B).

107 The median duration of infections based on a positive PCR test in the vaccinated subjects was 2  
108 days (Interquartile range - IQR: 2-4). Notably, this duration was significantly shorter than post-  
109 natural infections (16.5 days; IQR: 11-40.5;  $P<0.001$ ) or re-infections (11 days; IQR 4-21;  
110  $P=0.0035$ ) in the pre-vaccinated subjects, suggesting significantly shorter duration of viral shedding  
111 in vaccinated individuals as compared to the unvaccinated ones (Table S3 and Figure 2). Moreover,  
112 to our knowledge, all infected individuals reported asymptomatic or pauci-symptomatic infections.

113

#### 114 **Correlations with IgG levels of SARS-CoV-2 infections in vaccine responders**

115 The frequency of molecularly detectable infections among the IgG+ vaccine-responders (subjects  
116 that positively responded to vaccination) was significantly lower (1,4%) than in the IgG+ non-  
117 vaccinated subjects after natural infection (9%;  $P=0.0002$ ) and the IgG- vaccine non-responders  
118 (5.7%;  $P=0.042$ ) (Table 2).

119 Among the newly infected vaccinated-subjects, 3 cases were IgG non-responders (IgG-). Notably,  
120 the remaining 27 infected vaccinated individuals were mainly distributed in the lower quartiles of  
121 anti-RBD antibody titers (~74% in quartiles 1 and 2; Table 1B and Figure 1).

122

## 123 **Discussion**

124 Our surveillance study yielded three main findings: i) the probability of infections after COVID-19  
125 vaccine is lower than after natural infection; ii) the few SARS-CoV-2 infections occurring in  
126 individuals who mounted a serologically positive response to vaccination are of significantly shorter  
127 duration than the first infections in non-vaccinated individuals; iii) the levels of anti-SARS-CoV-2  
128 circulating IgGs were inversely correlated with the frequency and duration of viral detection, as  
129 recently reported [11].

130 This cohort study in healthy workers conducted from the end of the first wave confirmed that  
131 reinfection after natural infection is seven times more likely than infection after vaccination. This  
132 finding supports the CDC recommendation that all eligible persons be offered COVID-19  
133 vaccination, regardless of previous SARS-CoV-2 infection status. However, the probability of  
134 reinfection largely depends on pre-existent IgG positivity. Thus, serological testing in vaccinated  
135 individuals might help to identify the population at higher risk of infection.

136 Reinfections have been reported internationally since June 2020, although they remain uncommon:  
137 test results of 4 million people in Denmark found that < 1% of persons who tested positive for  
138 SARS-CoV-2 experienced reinfection [12]. The vastly shorter duration of post-vaccine infections  
139 likely has major impacts on models to predict epidemiological dynamics, which critically rely on  
140 this parameter [13, 14], and may suggest a modification of the isolation policies, which still  
141 recommend releasing from isolation 10 days after a first positive PCR test for asymptomatic testing,  
142 without distinction for vaccinated subjects [15].

143 Large longitudinal cohort studies with regular testing are needed to provide systematic  
144 epidemiological, virological, immunological, and clinical data useful to understand the rates of

145 reinfection and their implications for health policies. Moreover, data presented in this study will  
146 need to be updated to estimate the impact of the delta variant on reinfection/post-vaccine infection  
147 risk, considering that the delta variant was not diffuse in our country at the time of testing described  
148 in our study.

149

## 150 **Conclusions**

151 Overall, our data show that individuals who responded to vaccination based on the detection of anti-  
152 RBD antibodies were still susceptible to SARS-CoV-2 productive infection, suggesting caution,  
153 especially for healthcare workers that are daily in contact with fragile patients, such as cancer  
154 patients in our Institute. However, the probability of infection after vaccination is rare and  
155 significantly less frequent compared to reinfection after natural infection, in particular in  
156 responders, which are the vast majority. Furthermore, the duration of infection in vaccinated  
157 individuals is significantly shorter to the one observed post-natural infection, suggesting that post-  
158 vaccination viral shedding is likely very limited, recommending for a revision of the isolation  
159 policies, that could drastically reduce the time of quarantine, with clear important social and  
160 economical implications.

161

## 162 **Acknowledgements**

163 We thank Fondazione Europea Guido Venosta, National Instruments Corporation, Ralph Lauren  
164 and Fondo MFS for funding this research and Fondazione IEO-CCM for fund-raising.

165

## 166 **Competing interests**

167 The authors declare no conflict of interest

168

169

170

171 **References**

- 172 1. Dopico XC, Ols S, Loré K, Hedestam GBK. Immunity to SARS-CoV-2 induced by  
173 infection or vaccination. *J Intern Med* 2021; 00:1–19. doi: 10.1111/joim.13372
- 174 2. Grigoryan L, Bali Pulendran B. The immunology of SARS-CoV-2 infections and vaccines.  
175 *Semin Immunol.* 2020; 50:101422. doi: 10.1016/j.smim.2020.101422
- 176 3. Low JS, Vaqueirinho D, Mele F, Foglierini M, Jerak J, Perotti M et al. Clonal analysis of  
177 immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2.  
178 *Science.* 2021 Jun 18;372(6548):1336-1341.
- 179 4. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S. et al. Safety and  
180 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.* 2020; 383:2603-15.
- 181 5. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Safety and  
182 efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim  
183 analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet.*  
184 2021; 397:99-111.
- 185 6. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and  
186 effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19  
187 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an  
188 observational study using national surveillance data. *Lancet.* 2021; 397(10287):P1819-29.
- 189 7. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA  
190 Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med.*  
191 2021;384(15):1412-23.
- 192 8. Vahidy FS, Pischel L, Tano ME, Pan AP, Boom ML, Sostman HD, et al. Real World  
193 Effectiveness of COVID-19 mRNA Vaccines against Hospitalizations and Deaths in the  
194 United States. *medRxiv [Preprint].* 2021. doi: 10.1101/2021.04.21.21255873.



- 195 9. Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness  
196 of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms,  
197 hospital admissions, and mortality in older adults in England: test negative case-control  
198 study. *BMJ*. 2021; 373:n1088.
- 199 10. Bruni M, Cecatiello V, Diaz-Basabe A, Lattanzi G, Mileti E, Monzani S et al. Persistence of  
200 Anti-SARS-CoV-2 Antibodies in Non-Hospitalized COVID-19 Convalescent Health Care  
201 Workers. *J Clin Med*. 2020; 9(10): 3188
- 202 11. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA et al. Neutralizing  
203 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2  
204 infection. *Nat Med*. 2021; 27 (7): 1205-1211
- 205 12. Hansen CH, Michlmayr D, Gubbels SM, Molbak K, Ethelberg S. Assessment of protection  
206 against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark  
207 in 2020: a population-level observational study. *Lancet*. 2021; 397:1204-1212
- 208 13. Bartsch MS, Wedlock PT, O’Shea KJ, Cox SN, Strych U, Nuzzo JB, Ferguson MC et al.  
209 Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019  
210 Vaccination. *J Infect Dis*. 2021; jiab233. DOI: 10.1093/infdis/jiab233
- 211 14. Lee BY, Bartsch SM, Ferguson MC, Wedlock PT, O’Shea KJ, Siegmund SS et al. The value  
212 of decreasing the duration of the infectious period of severe acute respiratory syndrome  
213 coronavirus 2 (SARS-CoV-2) infection. *PLoS Comput Biol*. 2021;17(1):e1008470.
- 214 15. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of Severe Acute Respiratory Syndrome  
215 Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation? *Clin*  
216 *Infect Dis*. 2021;72(8):1467-1474. doi: 10.1093/cid/ciaa1249.

217  
218  
219

220 **Figure Legends**

221 **Figure 1.** IgG levels against the receptor binding domain (RBD) of the SARS-CoV-2 protein after 2  
222 doses of BNT162b2 vaccine. Individuals are divided by age groups. The red dots highlight the IgG  
223 levels in individuals that resulted positive to SARS-CoV-2 infection by qPCR. The dashed red line  
224 indicates the threshold of positivity for our serological test (positives>0.28). Boxes define the 25th  
225 and the 75th percentiles; horizontal line within the boxes indicates the median and whiskers define  
226 the 5th and the 95th percentiles. B, as for panel A after 1 dose of AstraZeneca (AZ) vaccine.

227

228 **Figure 2.** Time of SARS-CoV-2 infections. Kaplan-Meier curves of natural infections (black line);  
229 natural reinfections (green line); infections post-vaccine (red line). P-value, Log-rank test.

230

231 **Tables**

232 **Table 1A: study population**

Age group (y)	All	Gender		Tested post vaccination			Vaccine	
	Nr	M	F	Nr	M	F	BNT162b2 (1 dose)	AZD1222 (1 dose)
19-29	456	145	311	429	138	291	354 (10)	56 (12)
30-39	510	193	317	483	185	298	424 (11)	39 (14)
40-49	547	161	386	531	158	373	488 (12)	24 (10)
50-59	451	155	296	432	153	279	406 (10)	9 (12)
60-69	132	56	76	130	55	75	122 (5)	4 (0)
70-81	25	17	8	24	16	8	24 (0)	1 (0)
<b>Total Nr</b>	<b>2121</b>	<b>727</b>	<b>1394</b>	<b>2029</b>	<b>705</b>	<b>1324</b>	<b>1818 (48)</b>	<b>133 (48)</b>

233

234 **Table 1B: SARS-Cov2-positive individuals post-vaccination**

Subjects	Age range	Days post-vaccination	E gene	RdRP gene	N gene	anti-RBD IgG (range 0.28-35)	IgG quartile (min 1, max 4)*	Vaccine
ID1	36-40	7	n	n	38.96	10.65	1	II jabs BNT162b2
ID2	31-35	5	n	n	35.80	25.81	4	II jabs BNT162b2
ID3	26-30	7	n	n	38.32	24.67	3	II jabs BNT162b2
ID4	21-25	11	38.98	n	36.91	0.55	1	II jabs BNT162b2
ID5	61-65	8	31.41	35.04	33.14	27.66	4	II jabs BNT162b2
ID6	41-45	42	n	37.67	n	6.10	2	II jabs BNT162b2
ID7	45-50	12	30.29	33.73	31.92	12.11	2	II jabs BNT162b2
ID8	41-45	40	25.35	27.27	27.15	3.28	1	II jabs BNT162b2
ID9	41-45	23	n	n	38,9	5.84	3	I jab AZ
ID10	51-55	21	22.85	25.45	24.56	0.45	2	I jab AZ
ID11	56-60	46	21.76	23.78	22.76	9.48	2	II jabs BNT162b2
ID12	41-45	53	21.4	22.79	19.69	4.57	1	II jabs BNT162b2
ID13	46-50	55	36.58	38.78	34.4	8.64	3	II jabs BNT162b2
ID14	36-40	53	28.77	31.61	29.85	6.76	2	II jabs BNT162b2
ID15	51-55	67	29.06	31.89	28.65	1.21	1	II jabs BNT162b2
ID16	31-35	21	37.16	n	34.74	0.21	1	I jab AZ
ID17	46-50	72	n	n	37.12	3.09	2	II jabs BNT162b2
ID18	26-30	55	n	n	37.34	4.98	4	I jab AZ
ID19	51-55	98	21.05	23.17	20.56	3.25	3	II jabs BNT162b2
ID20	46-50	98	30.03	32.52	28.61	0.69	1	II jabs BNT162b2
ID21	51-55	91	n	n	37.01	1.59	2	II jabs BNT162b2
ID22	56-60	88	n	38.37	n	2.29	3	II jabs BNT162b2
ID23	46-50	68	n	38.83	n	2.88	1	II jabs BNT162b2
ID24	46-50	98	n	n	37.04	1.69	2	II jabs BNT162b2
ID25	51-55	99	n	n	36.88	0.26	1	II jabs BNT162b2
ID26	46-50	108	n	n	36.90	3.69	1	II jabs BNT162b2
ID27	41-45	75	35.89	36.94	35.87	6.50	4	II jabs BNT162b2
ID28	46-50	78	n	n	36.07	0.71	1	II jabs BNT162b2
ID29	31-35	116	n	n	37.25	3.06	3	II jabs BNT162b2
ID30	56-60	139	12.41	15.61	11.68	0.22	1	II jabs BNT162b2

235 \* quartiles normalized to age and time after vaccination; n, not detectable


**Table 2. Frequency of natural reinfections and infections after vaccination by IgG status**

				IgG-			IgG+		
	Natural infections pre vaccine	Vaccinated Subjects	P-value	Natural infections pre vaccine	Vaccinated Subjects	P-value	Natural infections pre-vaccine	Vaccinated Subjects	P-value
<b>All</b>	84 (100%)	2029 (100%)		4 (100%)	53 (100%)		80 (100%)	1967 (100%)	
<b>No PCR+ swab</b>	76 (90.5%)	1999 (98.5%)	<0.0001	3 (75%)	50 (94.3%)	0.259	73 (91%)	1940 (98.6%)	0.0001
<b>PCR+ after natural infection and after vaccine</b>	8 (9.5%)	30 (1.5%)		1 (25%)	3 (5.7%)		7 (9%)	27 (1.4%)	


IgG+ values are assessed at baseline for the cohort pre-vaccination and 1 week post-vaccination for the second cohort.

**A**


1 week after 2nd dose BNT162b2




1 month after 2nd dose BNT162b2




2 months after 2nd dose BNT162b2




3 months after 2nd dose BNT162b2




4 months after 2nd dose BNT162b2

**B**

1 week after 1st dose AZ



1 month after 1st dose AZ



2 months after 1st dose AZ

